Literature DB >> 21322079

Prognosis: a variable parameter: dynamic prognostic modeling in head and neck squamous cell carcinoma.

Marc P van der Schroeff1, Ewout W Steyerberg, Marjan H Wieringa, Ton P M Langeveld, Jan Molenaar, Robert J Baatenburg de Jong.   

Abstract

BACKGROUND: In general, the estimated prognosis of patients with cancer is based on patient characteristics known at the time of diagnosis and presented as if a lifetime verdict. However, the prognosis of patients with cancer who survive the first critical years changes, along with the prognosis for those with local or regional recurrences or distant metastases.
METHODS: This study concerns 2927 patients with a primary head and neck squamous cell carcinoma (HNSCC). We developed prognostic models after initial treatment and at different time points during follow-up.
RESULTS: The developed models show the effects of survival time, recurrences, and distant metastasis during follow-up. The C-statistics ranged from 0.76 to 0.69.
CONCLUSION: Prognosis is dynamic: the passage of time and the occurrence of life events change the predicted probabilities of survival. The models enhance our insight in the effect of recurrences and metastasis during follow-up and could be used for better patient counseling.
Copyright © 2010 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2011        PMID: 21322079     DOI: 10.1002/hed.21693

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  6 in total

1.  Plasma tumor necrosis factor-α and C-reactive protein as biomarker for survival in head and neck squamous cell carcinoma.

Authors:  Bengt-Åke Andersson; Freddi Lewin; Jan Lundgren; Mats Nilsson; Lars-Erik Rutqvist; Sture Löfgren; Nongnit Laytragoon-Lewin
Journal:  J Cancer Res Clin Oncol       Date:  2014-01-31       Impact factor: 4.553

2.  The COMPLETE trial: HolistiC early respOnse assessMent for oroPharyngeaL cancEr paTiEnts; Protocol for an observational study.

Authors:  Gerda M Verduijn; Marta E Capala; Nienke D Sijtsema; Iris Lauwers; Juan A Hernandez Tamames; Wilma D Heemsbergen; Aniel Sewnaik; Jose A Hardillo; Hetty Mast; Yvette van Norden; Maurice P H M Jansen; Aad van der Lugt; Dik C van Gent; Mischa S Hoogeman; Bianca Mostert; Steven F Petit
Journal:  BMJ Open       Date:  2022-05-18       Impact factor: 3.006

Review 3.  Metastatic disease in head & neck oncology.

Authors:  Paolo Pisani; Mario Airoldi; Anastasia Allais; Paolo Aluffi Valletti; Mariapina Battista; Marco Benazzo; Roberto Briatore; Salvatore Cacciola; Salvatore Cocuzza; Andrea Colombo; Bice Conti; Alberto Costanzo; Laura Della Vecchia; Nerina Denaro; Cesare Fantozzi; Danilo Galizia; Massimiliano Garzaro; Ida Genta; Gabriela Alejandra Iasi; Marco Krengli; Vincenzo Landolfo; Giovanni Vittorio Lanza; Mauro Magnano; Maurizio Mancuso; Roberto Maroldi; Laura Masini; Marco Carlo Merlano; Marco Piemonte; Silvia Pisani; Adriele Prina-Mello; Luca Prioglio; Maria Gabriella Rugiu; Felice Scasso; Agostino Serra; Guido Valente; Micol Zannetti; Angelo Zigliani
Journal:  Acta Otorhinolaryngol Ital       Date:  2020-04       Impact factor: 2.124

4.  Noncompliance to guidelines in head and neck cancer treatment; associated factors for both patient and physician.

Authors:  Emilie A C Dronkers; Steven W Mes; Marjan H Wieringa; Marc P van der Schroeff; Robert J Baatenburg de Jong
Journal:  BMC Cancer       Date:  2015-07-11       Impact factor: 4.430

5.  Treatments and costs for recurrent and/or metastatic squamous cell carcinoma of the head and neck in the Netherlands.

Authors:  Naomi van der Linden; Jan Buter; Chris P Pescott; Roy I Lalisang; Jan Paul de Boer; Alexander de Graeff; Carla M L van Herpen; Robert J Baatenburg de Jong; Carin A Uyl-de Groot
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-01-21       Impact factor: 2.503

6.  Absent and abundant MET immunoreactivity is associated with poor prognosis of patients with oral and oropharyngeal squamous cell carcinoma.

Authors:  Maria J De Herdt; Stefan M Willems; Berdine van der Steen; Rob Noorlag; Esther I Verhoef; Geert J L H van Leenders; Robert J J van Es; Senada KoljenoviÄ; Robert J Baatenburg de Jong; Leendert H J Looijenga
Journal:  Oncotarget       Date:  2016-03-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.